Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 2/20 | 0.58 |
| ▸ | RAB9A | P51151 | 2/20 | 0.58 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.54 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.48 |
| ▸ | GRIN2B | Q13224 | 6/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12660048 | 0.87 | SMN1; SMN2 (0.57) | SMN1; SMN2CYP2C19NPC1RAB9ALNPEP | |
| SCHEMBL29942602 | 0.87 | SMN1; SMN2 (0.57) | SMN1; SMN2CYP2C19NPC1RAB9ALNPEP | |
| SCHEMBL23301488 | 0.87 | SMN1; SMN2 (0.57) | SMN1; SMN2CYP2C19NPC1RAB9ALNPEP | |
| SCHEMBL13198831 | 0.87 | SMN1; SMN2 (0.63) | SMN1; SMN2CYP2C19NPC1RAB9ALNPEP | |
| SCHEMBL21854787 | 0.85 | SMN1; SMN2 (0.56) | SMN1; SMN2CYP2C19NPC1RAB9ALNPEP | |
| SCHEMBL30120062 | 0.85 | SMN1; SMN2 (0.60) | SMN1; SMN2CYP2C19NPC1RAB9ALNPEP | |
| SCHEMBL309611 | 0.84 | SMN1; SMN2 (0.55) | SMN1; SMN2CYP2C19NPC1RAB9ALNPEP | |
| SCHEMBL1641404 | 0.82 | SMN1; SMN2 (0.58) | SMN1; SMN2CYP2C19NPC1RAB9ALNPEP | |
| SCHEMBL4717723 | 0.82 | SMN1; SMN2 (0.62) | SMN1; SMN2CYP2C19NPC1RAB9ALNPEP | |
| SCHEMBL30012105 | 0.82 | GPR119 (0.53) | SMN1; SMN2CYP2C19NPC1RAB9ALNPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7767674-B2 | Kinase inhibitors | ELI LILLY AND COMPANY (US) | 2010-08-03 | — | — | US | disclosed |
| US-20080306068-A1 | Suppression cytokines, tumor necrosis factor | ELI LILLY AND COMPANY (US) | 2008-12-11 | — | — | US | disclosed |
| EP-1761520-B1 | KINASE INHIBITORS | LILLY CO ELI (US) | 2008-07-09 | — | — | EP | disclosed |
| EP-1761520-A1 | KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2007-03-14 | — | — | EP | disclosed |
| WO-2006009741-A1 | KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2006-01-26 | — | — | WO | disclosed |
| EP-1609789-A1 | UREIDO-PYRAZOLE DERIVATIVES AND THEIR USE AS KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2005-12-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306068-A1 | Suppression cytokines, tumor necrosis factor | TNF, TNFRSF1A, IL2 | SMN1; SMN2 4848/4885CYP2C19 4364/4885NPC1 3855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.